Payment overview · 2025
General Payments
$2,317.47
79 reported records · 19 companies
Healthcare provider profile · identity verified
Eric Steed Jackson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EVANSVILLE, IN · NPI 1245317429
Verified facts
What the public records show
CMS Open Payments records show Eric Steed Jackson, M.D. received $2,317.47 in general payments during 2025 across 79 reported records.
Shionogi Inc accounted for 49.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shionogi Inc | Unresolved — no canonical attribution shown | $1,137.50 | 49.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $324.70 | 14.0% | 27 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $167.75 | 7.2% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $166.80 | 7.2% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.84 | 3.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.28 | 2.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.63 | 2.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.66 | 1.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.44 | 1.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.88 | 1.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.92 | 1.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.72 | 1.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.55 | 1.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.55 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.26 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.24 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.39 | 0.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.13 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.23 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,179.97 | 78 |
| Consulting Fee | $1,137.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| S-217622 Normalized: s 217622 |
Drug | Shionogi Inc | $1,137.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $252.30 | 18 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $229.55 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $205.68 | 14 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $167.75 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.28 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.28 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.63 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.02 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.37 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $27.72 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.55 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $10.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 138 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 138 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
138 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 708 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 639 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 628 | 155 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 408 | 104 |
| Omeprazole | Omeprazole | 396 | 119 |
| Losartan Potassium | Losartan Potassium | 380 | 109 |
| Lisinopril | Lisinopril | 357 | 99 |
| Simvastatin | Simvastatin | 349 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 341 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 277 | 73 |
| Gabapentin | Gabapentin | 274 | 58 |
| Lorazepam | Lorazepam | 266 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 61 |
| Tramadol Hcl | Tramadol Hcl | 246 | 49 |
| Furosemide | Furosemide | 231 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 58 |
| Metformin Hcl Er | Metformin Hcl | 220 | 61 |
| Allopurinol | Allopurinol | 172 | 45 |
| Clonazepam | Clonazepam | 163 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 161 | 24 |
| Potassium Chloride | Potassium Chloride | 151 | 44 |
| Prednisone | Prednisone | 149 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 38 |
| Valsartan | Valsartan | 140 | 36 |
| Eliquis | Apixaban | 138 | 36 |
| Synthroid | Levothyroxine Sodium | 138 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 33 |
| Meloxicam | Meloxicam | 130 | 31 |
| Metformin Hcl | Metformin Hcl | 129 | 36 |
| Ezetimibe | Ezetimibe | 126 | 33 |
| Alprazolam | Alprazolam | 125 | 27 |
| Sertraline Hcl | Sertraline Hcl | 125 | 31 |
| Trazodone Hcl | Trazodone Hcl | 125 | 34 |
| Irbesartan | Irbesartan | 120 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 38 |
| Memantine Hcl | Memantine Hcl | 117 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 25 |
| Glimepiride | Glimepiride | 108 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 31 |
| Ozempic | Semaglutide | 102 | 22 |
| Atenolol | Atenolol | 99 | 29 |
| Famotidine | Famotidine | 97 | 27 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 97 | 25 |
| Cefuroxime | Cefuroxime Axetil | 88 | 68 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 35 |
| Diazepam | Diazepam | 82 | 23 |
| Farxiga | Dapagliflozin Propanediol | 82 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 22 |
| Glipizide Er | Glipizide | 80 | 24 |
| Montelukast Sodium | Montelukast Sodium | 78 | 19 |
| Xarelto | Rivaroxaban | 71 | 13 |
| Buspirone Hcl | Buspirone Hcl | 69 | 15 |
| Januvia | Sitagliptin Phosphate | 68 | 15 |
| Fenofibrate | Fenofibrate | 67 | 16 |
| Pregabalin | Pregabalin | 67 | 17 |
| Donepezil Hcl | Donepezil Hcl | 65 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 62 | 17 |
| Bupropion Xl | Bupropion Hcl | 61 | 17 |
| Carvedilol | Carvedilol | 61 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 60 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 14 |
| Clonidine Hcl | Clonidine Hcl | 57 | 13 |
| Celecoxib | Celecoxib | 56 | 12 |
| Mirtazapine | Mirtazapine | 56 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 19 |
| Jardiance | Empagliflozin | 54 | suppressed |
| Azithromycin | Azithromycin | 52 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 13 |
| Benazepril Hcl | Benazepril Hcl | 49 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 11 |
| Klor-Con M20 | Potassium Chloride | 43 | 15 |
| Eszopiclone | Eszopiclone | 42 | 11 |
| Spironolactone | Spironolactone | 42 | 13 |
| Topiramate | Topiramate | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 11 |
| Finasteride | Finasteride | 40 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 37 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 34 | 12 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Estradiol | Estradiol | 33 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | 11 |
| Propranolol Hcl | Propranolol Hcl | 31 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Testosterone | Testosterone | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 19 |
| Armour Thyroid | Thyroid,pork | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 20 |
| Nabumetone | Nabumetone | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,317.47 · 79 records | Shionogi Inc | ABRYSVO, AREXVY, Auvelity, CAMZYOS, CAPLYTA, COMIRNATY, ELIQUIS, FANAPT, GEMTESA, INSPIRE, JARDIANCE, MINIMED 780G, MOUNJARO, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, S-217622, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, TRUMENBA, UBRELVY, VOQUEZNA, VRAYLAR, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error